Sunday, February 22, 2015 5:19:59 PM
We believe this drug represents an estimated $600 million U.S. market.
at least you could laugh today
, mission accomplished, some see the glass always half empty, very sad but everyone's own choice. Some institutional investors seem to be bullish on this stock and they see the potential,(they put their money where their mouth is) it looks like it is worth the gamble for them. This company has changed for the good and trials are moving with funds in place and FDA fast track status, we could all be in for a nice surprise.
I am long and I stay long and will increase the position steadily, you do not need to feel sorry for any longs as it is everyone's own decision out of free will.
Recent TENX News
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
